Abstract
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Current Drug Targets
Title: Ketamine: New Indications for an Old Drug
Volume: 6 Issue: 7
Author(s): M. G. Annetta, D. Iemma, C. Garisto, C. Tafani and R. Proietti
Affiliation:
Keywords: ketamine, analgesia, opioids
Abstract: Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Export Options
About this article
Cite this article as:
Annetta G. M., Iemma D., Garisto C., Tafani C. and Proietti R., Ketamine: New Indications for an Old Drug, Current Drug Targets 2005; 6 (7) . https://dx.doi.org/10.2174/138945005774574533
DOI https://dx.doi.org/10.2174/138945005774574533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytochrome P450 in Neurological Disease
Current Drug Metabolism Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry Design, Characterization and Evaluation of Anti-epileptic Activity of Nanoprecipitating Preconcentrate of Carbamazepine
Drug Delivery Letters Molecular Mechanisms of Cytochrome P450 Induction: Potential for Drug-Drug Interactions
Current Protein & Peptide Science Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology ORO-Dental Manifestations in West Syndrome
Current Topics in Medicinal Chemistry Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Organotypic Brain Slices of ADULT Transgenic Mice: A Tool to Study Alzheimer’s Disease
Current Alzheimer Research Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data
CNS & Neurological Disorders - Drug Targets Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Comparative Study of LC/MS and EMIT in Therapeutic Monitoring of Carbamazepine and its Clinical Applications
Current Pharmaceutical Analysis Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Editorial (Thematic Issue: The Activity of Products From Cnidaria: A Therapeutic Tool in Neurological Diseases? Part II)
Central Nervous System Agents in Medicinal Chemistry Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets AMPA Receptor Antagonists for the Treatment of Stroke
Current Drug Targets - CNS & Neurological Disorders Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging Graphical Abstracts
Letters in Drug Design & Discovery